Annual review of pharmacology and toxicology

Annu Rev Pharmacol Toxicol · ISSN (print) 0362-1642 · 4 papers in corpus
2026
doi:10.1146/annurev-pharmtox-062124-043519 ·PMID:40967235

We explore three emerging molecular pathways driving neuroinflammation in chronic and acute brain diseases: the EP2 receptor for prostaglandin E2, the CCR2 receptor for chemokine CCL2, and JAK/STAT signaling. Inflammation is now recognized …

2021
doi:10.1146/annurev-pharmtox-010919-023238 ·PMID:32976736

Chronic pain treatment remains a sore challenge, and in our aging society, the number of patients reporting inadequate pain relief continues to grow. Current treatment options all have their drawbacks, including limited efficacy and the pro…

2018
doi:10.1146/annurev-pharmtox-010617-052844 ·PMID:28992429

Over 70% of Americans take some form of dietary supplement every day, and the supplement industry is currently big business, with a gross of over $28 billion. However, unlike either foods or drugs, supplements do not need to be registered o…

review 1996
doi:10.1146/annurev.pa.36.040196.000403 ·PMID:8725382

Antiprogestins are characterized by substitutions at the 11 beta and 17 alpha positions of the steroid ring system and bind strongly to both progesterone and glucocorticoid receptors. Although they function predominantly as antiprogestins a…